Infectious Disease and Microbiology – Emmonsia parva

Overview

Emmonsia parva is a filamentous fungus (mold) that is a rare cause of human infection. Although infection is uncommon worldwide, the organism has been associated with several forms of localized and invasive fungal disease, particularly in immunocompromised patients.

Reported manifestations include osteomyelitis, prosthetic valve endocarditis, respiratory and sinonasal infections, central nervous system extension, pneumonia, and disseminated disease.

Microbiologic Characteristics

Emmonsia parva is a:

• Filamentous fungus

• Mold

• Rare human fungal pathogen

Human disease caused by this organism is uncommon.

Epidemiology

E. parva has a worldwide distribution, but clinically significant human infection is rare.

Severe or disseminated disease is more likely to occur in individuals with impaired immune defenses.

Clinical Infections

A variety of uncommon infections have been attributed to E. parva, including:

• Osteomyelitis

• Prosthetic valve endocarditis

• Rhinitis

• Sinusitis

• CNS extension from sinus disease

• Pneumonia

• Disseminated infection

Osteomyelitis

Rare cases of E. parva osteomyelitis have been reported.

Fungal involvement of bone may produce a chronic infection requiring both prolonged antifungal therapy and, in selected cases, surgical management.

Prosthetic Valve Endocarditis

E. parva has rarely been associated with prosthetic valve endocarditis.

Fungal prosthetic valve infections are potentially serious because eradication can be difficult with antifungal therapy alone.

Rhinitis and Sinusitis

The organism may produce rhinitis or sinusitis.

Although these infections are rare, invasive sinus disease can potentially spread beyond the sinonasal structures.

CNS Extension

A particularly serious complication is extension of sinus infection into the central nervous system.

This represents an invasive form of disease requiring aggressive management.

Pneumonia

E. parva may occasionally cause pulmonary infection or pneumonia.

Pulmonary disease is especially concerning in patients with significant immunosuppression.

Disseminated Infection

In immunocompromised patients, infection may spread beyond its original site and produce disseminated fungal disease.

Multiple organs may potentially become involved in severe invasive infection.

Diagnosis

Diagnosis is established through:

• Fungal culture

• Identification of the fungus in tissue biopsy specimens

Because infection is rare, demonstrating fungal elements within affected tissue can be particularly important in establishing the organism’s clinical significance.

Tissue Biopsy

Histopathologic examination of a tissue biopsy can demonstrate fungal structures within the lesion.

Culture of biopsy material can then assist with definitive identification of the pathogen.

Thus, diagnosis often depends on a combination of:

Compatible lesion + tissue evidence of fungus + positive culture

Treatment

The treatment described in the source is:

Intravenous amphotericin B

This is used particularly for serious or invasive infection.

Surgical Management

Surgical intervention can be an important component of management.

Removal or debridement of infected lesions may help control localized disease and reduce the fungal burden.

Surgery may be particularly relevant when infection involves:

• Bone

• Localized masses or lesions

• Invasive sinus disease

• Prosthetic material

High-Yield Clinical Pattern

Immunocompromised patient

• ●

Unusual invasive fungal infection

• ●

Pneumonia, sinusitis with CNS extension, osteomyelitis, or dissemination

• ●

Filamentous fungus identified in culture or tissue

→ Consider Emmonsia parva

Exam Essentials

Organism: Emmonsia parva

Type: Filamentous fungus (mold)

Distribution: Worldwide

Frequency: Rare human pathogen

Important risk group: Immunocompromised patients

Possible infections: Osteomyelitis, prosthetic valve endocarditis, rhinitis, sinusitis, CNS extension, pneumonia, and disseminated infection

Diagnosis: Culture + identification in tissue biopsy

Treatment described in source: IV amphotericin B

Additional management: Surgical removal/debridement of lesions

Key clinical pearl: Emmonsia parva is a rare filamentous fungal pathogen that can cause serious localized or disseminated disease, especially in immunocompromised patients; diagnosis relies on culture and tissue identification, while treatment traditionally involves amphotericin B plus surgical management when appropriate.